Isolation and structural confirmation of N-desmethyl topotecan, a metaboliteof topotecan

Cancer Chemotherapy and Pharmacology

Volumn 39, Issue 6, 1997, Pages 498-504

  Rosing, H ^a   Herben, V M M ^a   Van Gortel van Zomeren, D M ^a   Hop, E ^b   Kettenes van Den Bosch, J J ^b   Ten Bokkel Huinink, W W ^c   Beijnen, J H ^a,b,c  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Identification; Isolation; LC MS; Metabolite of topotecan; N desmethyl; Purification

Indexed keywords

DRUG METABOLITE; ETOPOSIDE; NORTOPOTECAN; TOPOTECAN; UNCLASSIFIED DRUG;

ARTICLE; CASE REPORT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG METABOLISM; DRUG PURIFICATION; DRUG URINE LEVEL; FEMALE; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MASS SPECTROMETRY; OVARY CANCER; PRIORITY JOURNAL; SOLID PHASE EXTRACTION;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; MASS SPECTROMETRY; SPECTROMETRY, FLUORESCENCE; TOPOTECAN;

EID: 0031016943     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050605     Document Type: Article

References (25)

1. Beijnen JH, Smith BR, Keijer WJ, Gijn R van, Bokkel Huinink WW ten, Vlasveld LT, Rodenhuis S, Underberg WJM (1990) High performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma. J Pharm Biomed Anal 8:789
2. Blaney SM, Balis FM, Cole DE, Craig C, Reid JM, Ames MM, Krailo M, Reaman G, Hammond D, Poplack D (1993) Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-h continuous infusion. Cancer Res 53:1032
3. Boehm JC, Hecht SM, Holden KG, Johnson RK, Kingsbury WD (1991) Water-soluble camptothecin analogs. Patent 5,004,758, 2 April 1991. U.S. Patent office, Washington, DC
4. Burris HA, Rothenberg ML, Kuhn JG, Von Hoff DD (1992) Clinical trials with the topoisomerase I inhibitors. Semin Oncol 19:663
5. Creemers GJ, Lund B, Verweij J (1994) Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat Rev 20:73
6. Cummings J, Smyth JF (1993) DNA topoisomerase I and II as targets for rational design of new anticancer drugs. Ann Oncol 4:533
7. Fassberg J, Stella VJ (1992) A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci 81:676
8. Herben VMM, Bokkel-Huinink WW ten, Rodenhuis S, Schornagel JH, Dubbelman R, Mandjes I, Beijnen JH (1996) Phase I and pharmacokinetic study of topotecan in combination with oral etoposide. Ann Oncol 7:472
9. Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Raphael B, Vinci RZ, Blum RH (1994) Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 12:553
10. Kingsbury WD, Boehm JC, Jakas DR, Holden KG, Hecht SM, Gallagher G, Caranfa MH, McCabe FL, Faucette LF, Johnson RK (1991) Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J Med Chem 34:98
11. Lynch TJ, Kalish L, Strauss G, Elias A, Skarin A, Shulman LN, Posner M, Frei E (1994) Phase II study of topotecan in metastatic non-small-cell lung cancer. J Clin Oncol 12:347
12. Mayer SE, Melmon KL, Gilman AG (1980) The dynamics of drug absorption, distribution, and elimination. In: Gilman AG, Goodman LS, Gilman A (eds), Goodman and Gilman's pharmacological basis of therapeutics (6th edn). Macmillan, New York, Toronto London, p 12
13. Pratt CB, Stewart C, Santana VM, Bowman L, Furman W, Ochs J, Marina N, Kuttesch JF, Heideman R, Sandlund JT, Avery L, Meyer WH (1994) Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol 12:539
14. Rang HP, Dale MM (1987) Absorption, distribution and fate of drugs. Pharmacology, Churchill Livingstone, London, Melbourne, New York, p 73
15. Recondo G, Abbruzzese J, Newman B, Newman R, Kuhn J, Hoff D von, Garteiz D, Raber M (1991) A phase I trial of topotecan administered by a 24-h infusion. Proc Am Soc Cancer Res 32:206
16. Rosing H, Doyle E, Davies BE, Beijnen JH (1995) High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone and carboxylate forms in human plasma. J Chromatogr 668:107
17. Rosing H, Doyle E, Beijnen JH (1996) The impact of column temperature in the high performance liquid chromatographic analysis of topotecan in rat and dog plasma. J Pharm Biomed Anal (in press)
18. Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kaufmann SH, Donehower RC (1992) Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 10:647
19. Slichenmeyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH (1993) The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85:271
20. Stewart CF, Baker SD, Heideman RL, Jones D, Crom WR, Pratt CB (1994) Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. J Clin Oncol 12:1946
21. Underberg WJM, Goossen RMJ, Smith BR, Beijnen JH (1990) Equilibrium kinetics of the new experimental antitumor compound SK&F 104864-A in aqueous solution. J Pharm Biomed Anal 8:681
22. Van Warmerdam LJC, Verweij J, Schellens JHM, Rosing H, Davies BE, Boer-Dennert M de, Maes RAA, Beijnen JH (1995) Pharmacokinetics and pharmacodynamics of topotecan administered daily for five days every three weeks. Cancer Chemother Pharmacol 35:237
23. Van Warmerdam LJC, Creemers GJ, Rodenhuis S, Rosing H, Boer-Dennert M de, Schellens JHM, Bokkel-Huinink WW ten, Davies BE, Maes RAA, Verweij J, Beijnen JH (1996) Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited sampling procedure. Cancer Chemother Pharmacol 38:254
24. Verweij J, Lund B, Beijnen JH, Planting A, Boer-Dennert M de, Koier I, Rosing H, Hansen H (1993) Phase I and pharmacokinetic study of topotecan, a new topoisomerase I inhibitor. Ann Oncol 4:673
25. Wall JG, Burris HA, Von Hoff DD, Rodriguez G, Kneuper-Hall R, Shaffer D, O'Rourke T, Brown T, Weiss G, Clark G, McVea S, Brown J, Johnson R, Friedman C, Smith B, Mann WS, Kuhn J (1992) A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenuous bolus every 21 days. Anticancer Drugs 3:337